Menu ×

HEALTHCARE & PHARMACEUTICAL

Hypertension Drugs Market Segmentation by Drug Class (Alpha Blockers, Beta Blockers, Diuretics, Vasodilators, Angiotensin Converting Enzyme [ACE] Inhibitors, Calcium Channel Blockers, Angiotensin II Receptor Blockers [ARB], Renin Inhibitors, and Others); by Type (Systemic and Pulmonary) and by Distribution Channel (Hospitals, Clinics, Research Laboratories and Retail Pharmacies) – Global Demand Analysis & Opportunity Outlook 2029

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

IN THE NEWS

  • April 30, 2018: Actelion Pharmaceuticals Ltd (Janssen Global Services, LLC) announced that it has submitted approval request to the U.S. Food and Drug Administration (FDA) for OPSUMIT (macitentan) for treating adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4).

  • March 2, 2020: AstraZeneca announced that it has completed the divestment agreement of its established hypertension medicines with Atnahs Pharma.

Introduction to Hypertension Drugs

Hypertension drugs are the class of drugs that are used to treat hypertension i.e., high blood pressure and other related disorders. Hypertension is a health condition where blood pressure increases above a maximum normal level. It also increases the risk of coronary heart disease and ischemic heart disease which are the leading causes of death worldwide. Hypertension leads to various other health problems such as it can lead to stroke, heart failure, heart attack and kidney diseases. The main purpose of hypertension drug is to lower and control high blood pressure and maintain blood pressure level in brain, heart, kidneys.

Market Size and Forecast

Rising cases of patients with hypertension owing to the presence of risk factors such as lifestyles changes, ignoring health problems as well as rise in stress levels are the significant factors boosting the market growth. The hypertension drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2021-2029. The market is segmented by drug class into alpha blockers, beta blockers, diuretics, vasodilators, angiotensin converting enzyme [ACE] inhibitors, calcium channel blockers, angiotensin II receptor blockers [ARB], renin inhibitors, and others. Among these segments, the segment for diuretics is anticipated to hold the leading share in the market on account of its high preference among majority of patients for hypertension treatment. Further, studies have shown that more than one-third of the adults having hypertension were reported to take diuretics, which is anticipated to drive the growth of the diuretics segment in the global hypertension drugs market. CLICK TO DOWNLOAD SAMPLE REPORT

Hypertension Drugs Market Share Segmentation by Drug

Growth Drivers

Lifestyle Changes and Rising Awareness for the Effects of Hypertension on Health to Boost the Market Growth

Hypertension being the most common health disorder among majority of the global population, the need for therapeutic treatment is increasing to control it at an early stage. Moreover, there has been growing prevalence of hypertension over the last few years owing to elevated stress levels and abrupt changes in lifestyle. According to the Centers for Disease Control and Prevention (CDC), in United States, 36,524 people died from essential hypertension and hypertensive renal disease in 2019. Additionally, increased awareness regarding hypertension and its available treatment options attributes to high demand for hypertension drugs. This is anticipated to significantly expand the hypertension drugs market.

Huge Investment in Healthcare R&D to Drive the Market Growth

The healthcare services all over the world is improving at a fast pace on account of advanced research in development of effective and novel drugs. Many companies are putting emphasis in increasing their efforts toward the discovery of new hypertension drugs in order to manage and control high blood pressure. Furthermore, increasing number of cases of various diseases is resulting in the growing demand for better healthcare services, facilities and equipment at clinics and hospitals. The growing research activities for treatment methods at research laboratories is further anticipated to fuel the healthcare industry. Such factors are anticipated to drive the growth of the global hypertension drugs market over the forecast period.

Restraints

Rising Number of Alternate Generic Drugs to Hamper the Market Growth

There is an increase in the number of generic drugs and other substitutes associated for the treatment of hypertension which negatively affects the market growth. Further, presence of some side-effects of these drugs is estimated to hinder the growth of the global hypertension drugs market in the future.

Market Segmentation

Our in-depth analysis of the global hypertension drugs market includes the following segments:

By Drug Class

  • Alpha Blockers
  • Beta Blockers
  • Diuretics
  • Vasodilators
  • Angiotensin Converting Enzyme [ACE] Inhibitors
  • Calcium Channel Blockers
  • Angiotensin II Receptor Blockers [ARB]
  • Renin Inhibitors
  • Others

By Type

  • Systemic
  • Pulmonary

By Distribution Channel

  • Hospitals
  • Clinics
  • Research Laboratories
  • Retail Pharmacies

By Region

On the basis of regional analysis, the global hypertension drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for hypertension drugs in North America is anticipated to hold the largest share in the market on account of the presence of leading market players in the region which manufacture and market hypertension drugs. Moreover, the expertise in rendering prompt and accurate diagnosis of hypertension, favorable reimbursement policies by the government and presence of advanced healthcare infrastructure in this region further increases the product demand. The market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of developing healthcare infrastructure and growing research activities in the region. Additionally, owing to the increasing age as a primary risk factor, the rise in geriatric population, especially in countries such as China, India and Japan are anticipated to raise the demand for hypertension drugs in the region.

The global hypertension drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved